Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.6 HKD | -2.51% | -3.79% | -1.20% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.20% | 601M | |
+48.39% | 765B | |
-6.13% | 354B | |
+20.61% | 331B | |
+10.00% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+5.80% | 164B | |
-2.50% | 162B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics Gets Nod to Register Iluvien in Hong Kong